The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
Related Posts
Trump vs. Science
We explain the administration’s cuts to research.
NIH Research Grants Lag Behind Last Year’s by $1 Billion
After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding research into…
Your Inhalers and EpiPens Aren’t Very Healthy for the Environment
Single-use insulin pens changed Brian Brandell’s life. Growing up with Type 1 diabetes in the 1970s, he had to carry…